Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2004) 7 P21

BES2004 Poster Presentations Cytokines and growth factors (13 abstracts)

Responsiveness to growth hormone throughout the menstrual cycle

HK Gleeson & SM Shalet


Department of Endocrinology, Christie Hospital, Manchester, UK.


The GH-IGF-1 axis alters through the menstrual cycle. During the periovulatory period when oestrogen levels have risen serum growth hormone (GH) levels increase 2-fold. IGF-1 levels have been reported as unchanged or modestly increased in the periovulatory period. Similarly exogenous oestrogens also increase GH levels while IGF-1 levels have been reported as reduced, unchanged or increased. Peripheral responsiveness to GH as reflected by the IGF-1 response to an acute bolus of GH is reduced in women on exogenous oestrogens suggesting a state of relative GH resistance. It is unknown if endogenous oestrogen has a similar impact on the GH-IGF-1 axis. To investigate this possibility further normal women were challenged with the IGF-1 generation test at different stages of the menstrual cycle.

Nine healthy women (age 38(6)years (mean (sd)); BMI 25(4)kg/m2) with a regular menstrual cycle were recruited . An IGF-1 generation test, which involves a sc injection of 21IU (7mg) of GH,was performed in the early follicular(EF), periovulatory(PO) and midluteal(ML) phases . At baseline serum samples were assayed for oestradiol. Serum IGF-1 levels were measured at baseline and 24 hours after GH administration.

As expected oestradiol levels were lower in the EF compared with PO or ML phases (32.6(7.8)vs 69.6(16.2)vs 66.6(23.6)pg/ml respectively (p<0.001)). Baseline IGF-1 was lower whereas increment IGF-1 (peak minus baseline) was higher in the EF compared with PO or ML (Baseline:297.4(48.9)vs 335.0(55.2)vs 346.6(78.2)ng/ml (p=0.01); Increment IGF-1:234.4(69.7)vs 194.7(37.8)vs 185.2(37.3)ng/ml (p=0.008)). Peak IGF-1 was unchanged throughout (531.9(69.7)vs 529.7(60.0)vs 531.8(66.7)ng/ml (p=1)).

In conclusion baseline IGF-1 increases from mid-cycle onwards presumably due to an increase in GH secretion secondary to increased oestrogen. The reduction in increment IGF-1 from mid-cycle onwards may represent a reduction in peripheral sensitivity to GH, however the constant peak IGF-1 level throughout the menstrual cycle suggests that maximal capacity to generate IGF-1 is unchanged. Therefore the changes seen in the GH-IGF-1 axis with endogenous oestrogen differ from those seen in response to exogenous oestrogen.

Volume 7

23rd Joint Meeting of the British Endocrine Societies with the European Federation of Endocrine Societies

British Endocrine Societies 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts